HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

NCT05582278 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: D-TACE
DRUG: HAIC
DRUG: Lenvatinib
DRUG: tislelizumab

Sponsor

Wen Li